Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

National study aims to slash lung infections in preterm babies

NCT ID NCT07109791

Knowledge-focused Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will look at how often very low birth weight babies in Canadian NICUs get ventilator-associated pneumonia (VAP) and how these infections are treated. Researchers will compare different hospitals' approaches to diagnosis and care, with the goal of creating a shared, evidence-based national guideline. The study involves 1,500 infants and focuses on reducing infections and unnecessary antibiotic use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to standardized national guidelines that reduce lung infections and unnecessary antibiotic use in fragile newborns.
What could go wrong
This is an observational study, not a treatment trial. It collects existing data and may not directly change outcomes. Results depend on hospital cooperation and data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

STUDY POPULATION: The study population will include all VLBW infants admitted to participating tertiary NICUs in Canada from 2025-2028 inclusive, diagnosed with VAP at physicians' discretion during their admission.

Ages

Up to 24 weeks

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: * All VLBW infants admitted to participating tertiary NICUs in Canada * All neonatal VAP events diagnosed based on the physicians' discretion EXCLUSION CRITERIA: * Infants with major congenital anomalies * Infants with moribund status on admission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antibiotic-resistant organisms (AROS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia nosocomial infection Pneumonia, Ventilator-Associated Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antibiotic-resistant organisms (AROS) Bronchopulmonary dysplasia (BPD) Health-care associated infection (HAI) Ventilator-associated pneumonia (VAP), neonatal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Alexandra Hospital

    Edmonton, Alberta, T5H 3V9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.